ALK-Abello A/S Announces Posting Of Briefing Documents For FDA Advisory Committee Meeting On The Ragweed Sublingual Tablet
1/24/2014 9:21:31 AM
ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) today announced that the US Food and Drug Administration (FDA) has posted briefing documents for the Allergenic Products Advisory Committee meeting on 28 January to review Merck’s Biologic License Application (BLA) for the investigational ragweed sublingual allergy immunotherapy tablet.
Help employers find you! Check out all the jobs and post your resume.
comments powered by